USPTO serial 97170031
ISOMORPHIC LABS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 6, 2025
- Examiner
- DUENAS, TAYLOR S
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ISOMORPHIC LABS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Cynthia Johnson Walden
Cynthia Johnson Walden Fish & Richardson P.C.PO Box 1022Minneapolis, MN 55440-1022United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Downloadable computer software using artificial intelligence, machine learning, deep learning, and reinforcement learning for predicting protein structure, discovering pharmaceutical drugs, and developing pharmaceutical products; downloadable computer software, computer programs and computer software algorithms for manipulating received or inputted data generated in a virtual space in connection with artificial intelligence methods, natural language processing, natural language understanding, dialog systems, voice and speech recognition and text to speech systems, natural language human-machine interfaces, and predictive assistance technologies for protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development | ACTIVE | — |
| 042 | Software as a service (SAAS) services featuring software using artificial intelligence, machine learning, deep learning, and reinforcement learning for protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development; advanced product research, design and development in the field of artificial intelligence for protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development; research and development in the fields of artificial intelligence, machine learning, deep learning, and reinforcement learning technologies for protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development; technology research in the field of artificial intelligence, machine learning, deep learning, and reinforcement learning for use in protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development; providing online, non-downloadable computer software platforms using artificial intelligence, machine earning, deep learning, and reinforcement learning for protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development; testing of computing methods, computer software algorithms, computer software, and computer hardware for protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development; scientific, pharmaceutical, and medical research; scientific research in the field of computer software using artificial intelligence, machine learning, deep learning, and reinforcement learning for medical research, pharmaceutical research, protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development; product research and development; medical, pharmaceutical, and scientific research in the field of protein structure prediction, pharmaceutical drug discovery, pharmaceutical product development, and computational biology; scientific and technological services, namely, scientific research in the fields of analytics and data mining, data analysis, data transformation, data visualization, statistical analysis, artificial intelligence, machine learning and virtual reality, science, chemistry, physics, biology and scientific research, all for protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development; computer aided data analysis for scientific research purposes in the fields of artificial intelligence, machine learning, deep learning, reinforcement learning, building neural networks, data tree search, high performance computing, distributed computing, cloud computing, analytics and data mining, virtual reality, augmented reality, chemistry, physics, biology, all for protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development; computer modelling services; scientific services for the analysis of organic compounds; drug discovery services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Isomorphic Labs Limited
- Other trademarks owned by Isomorphic Labs Limited
- Other trademarks owned by Isomorphic Labs Limited
- Other trademarks in Class 009
- Other trademarks in Class 042
- Similar marks named ISOMORPHIC LABS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 14, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 14, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 14, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 14, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jul 14, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| May 6, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| May 6, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 18, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 18, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 12, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 30, 2025 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Jan 27, 2025 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Jan 27, 2025 | PCBG | PETITION TO DIRECTOR - CHANGE BASIS - GRANTED | — |
| Jan 11, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 11, 2025 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jan 6, 2025 | APET | ASSIGNED TO PETITION STAFF | — |
| Nov 20, 2024 | TPAD | TEAS PETITION TO AMEND BASIS RECEIVED | — |
| Nov 19, 2024 | EXT2 | SOU EXTENSION 2 FILED | — |
| Nov 19, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 18, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 17, 2024 | EX1G | SOU EXTENSION 1 GRANTED | — |
| May 17, 2024 | EXT1 | SOU EXTENSION 1 FILED | — |
| May 17, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 19, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 19, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 19, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Nov 21, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 26, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 26, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 6, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 21, 2023 | FIXD | ELECTRONIC RECORD REVIEW COMPLETE | — |
| Aug 18, 2023 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Aug 14, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 14, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 14, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 14, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 14, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 25, 2023 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| May 25, 2023 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 25, 2023 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 3, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 22, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 21, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 21, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 21, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 21, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 21, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 20, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 17, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 16, 2021 | NWAP | NEW APPLICATION ENTERED | — |